Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomark Diagnostics Inc (CSE: BUX )

0.2700 -0.0100 (-3.57%)
Official Closing Price Updated: 3:58 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,900
Open 0.2600
Bid (Size) 0.2800 (500)
Ask (Size) 0.2900 (15,000)
Prev. Close 0.2800
Today's Range 0.2600 - 0.2800
52wk Range 0.1500 - 0.3500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"),... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+28.57%
+28.57%
1 Month
+22.73%
+22.73%
3 Month
-14.29%
-14.29%
6 Month
+28.57%
+28.57%
1 Year
+28.57%
+28.57%

More News

Read More
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
Via Newsfile
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
Via Newsfile
Topics Death Intellectual Property
Exposures Death Intellectual Property
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Via Newsfile
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
Via Newsfile
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
Via Newsfile
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
Via Newsfile
Topics Climate Change
Exposures Climate
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Via Newsfile
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
Via Newsfile
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
Via Newsfile
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
Via Newsfile
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
BioMark Announces Change of Auditor
Via Newsfile
Biomark to Open a Diagnostic Laboratory in Quebec
Via Newsfile
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.